NOW AVAILABLE: For the Antimigraine Market – A SnapShot analysis of HCP targeted promotional messaging and DTC initiatives for 2016.

A high level of activity was observed in the antimigraine market during 2016, which increased by 44% over the previous year equaling a total of 251 new pieces received. The most recent entries to the market included Upsher-Smith and Supernus, which issued press releases updating healthcare professionals on the FDA approvals of Qudexy XR and Trokendi XR, respectively, for migraine prophylaxis. In addition, the first branded materials were received from Promius Pharma for Zembrace SymTouch and from Avanir Pharmaceuticals for Onzetra Xsail. Teva experienced a setback as marketing for Zecuity was suspended due to reports of adverse skin reactions. Pfizer maintained its leadership in terms of the proportion of promotional materials received as it introduced a new $4 savings card offer for Relpax intended to counteract the entry of a generic to the market. The Depakote family of products from AbbVie also stressed prescribing the brand over the generic by urging physicians to write “DAW” or their state’s required language, along with information on a savings offer of its own. New formulations were announced, including Treximet for pediatrics from Pernix Therapeutics and Depomed’s replacement of saccharin sodium and aspartame with sucralose in Cambia. Support was a priority across brands, with many products offering various tools and resources, such as migraine trackers, to assist patients with their treatment. Multiple campaigns were featured, including new and refreshed themes from Botox, Cambia, Onzetra Xsail, Relpax, and Zomig. Efficacy was often promoted by various brands in terms of time until “pain freedom” or reduced need for rescue medications. Additional insights into marketing strategies and channel utilization are available with a subscription.

2016 Antimigraine

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, our online database of virtually all digital and print promotion distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Markets: Christine Alongi at

Ex-US Markets: Robin Cefalo at